StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PuK Gaming Launches First Officially Licensed Fortnite Mobile Accessories Range27.10.2026 14:15:00 CET | Press release
LONDON, UK / ACCESS Newswire / October 27, 2026 / PuK Gaming LTD, the UK-based designer of premium mobile gaming accessories, today launched Drop 1 of its officially licensed Fortnite range, in a deal facilitated by Epic Games' licensing agency IMG Licensing. The five-product range offers console-grade control to how millions play Fortnite: on a phone. The PuK Thumbstick, PuK Triggers, PuK Link Cable and PuK Thumb Sleeves attach in seconds, no battery charge or pairing required; the whole ecosystem fits in your pocket. The Hot Drop Bundle includes three of the four products, plus a collector tin and zip case. Every Drop 1 product includes a code for a bonus in-game item, with the Thumbstick granting the Stage Dive Glider and the Hot Drop Bundle granting the Battle Call Emote. "Fortnite defines competitive play for mobile gamers," said Scotty Tidwell, CEO of PuK Gaming. "Drop 1 gives Fortnite players more ways to play on mobile with console-grade low-latency control and precision." PuK
QorusDocs Launches QPilot Workspace, Where People and AI Agents Build Winning Proposals Together27.10.2026 14:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / October 27, 2026 / QorusDocs, the pursuit intelligence platform for professional services, legal, technology services and architecture, engineering and construction (AEC) firms, today launched QPilot Workspace, a shared space where business development teams and AI agents complete every pursuit together, from the moment an opportunity opens to the signed contract. QPilot Workspace is guided by pursuit intelligence that grounds every proposal, pitch and RFP response in a firm's real people, projects and pursuit history. Service firms are fielding more RFPs than ever, according to QorusDocs' research. More than two-thirds (68%) saw proposal volume climb last year, with most having to decline participation in 10 to 19% of the RFPs they receive. "We're responding to more RFPs than ever with shorter turnaround times," said Heather Almquist, senior vice president at Marsh, a leading professional services firm. "One of the hardest parts is pulling together the
Formerra Adjusts Transportation Surcharge Amid Continued Freight and Logistics Pressures27.10.2026 14:00:00 CET | Press release
ROMEOVILLE, IL / ACCESS Newswire / October 27, 2026 / Formerra, a leader in performance materials distribution, announced an increase to its transportation surcharge to address continued cost escalation in the freight and logistics market. Beginning November 2, 2026, a surcharge of $450 per delivery will apply to all shipments across North, Central, and South America. Costs in the freight and logistics market have increased steadily as the industry navigates higher operating costs, tighter capacity, and a shortage of qualified drivers. At the same time, diesel prices reached an all-time high in September. "Freight costs across the Americas remain elevated, and we do not expect these pressures to ease in the near term," said Tom Kelly, Formerra CEO. "The adjustment helps offset market pressures beyond our control while enabling us to maintain the dependable service our customers count on from Formerra." Customers should contact their Formerra representative for more information. About F
Camino and Nittetsu Launch Next Phase of Detailed Engineering for the Puquios Copper Project in Chile with Ausenco27.10.2026 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 27, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that following the successful completion of the Critical Engineering Phase study with Ausenco, the company officially held the kickoff meeting to launch the next phase of detailed engineering services with Ausenco Chile Ltda. ("Ausenco") for the Puquios copper project (the "Puquios Project"). This transition into detailed engineering represents a major step forward in advancing the project, locking in technical specifications, and preparing the Puquios Project for the construction phase. Marcelo Bruna, CEO of the Puquios Joint Venture said, "With the commencement of detailed engineering, the executive team remains focused on strict milestone tracking and cost control as we progress towards breaking ground." Jay Chmelauskas, CEO of Camino further commented, "We are working closely with Nittetsu to finalize agreements to source a pote
Clean Air Metals Announces Auditor Review of Q2 Financial Statements26.10.2026 21:30:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / October 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that, as of October 22, 2026, the Company's auditor, Manning Elliott LLP, has completed a review of the Company's second quarter consolidated interim financial statements for the six-month period ended July 31, 2026 (the "Financial Statements"), which were included in the Company's management information circular dated October 14, 2026, in connection with the Company's upcoming annual general and special meeting scheduled for November 13, 2026. No amendments were made to the Financial Statements as a result of the auditor's review, other than the removal of the "Notice of No Auditor Review." Upcoming Annual General and Special Meeting of Shareholders Additionally, Clean Air Metals' shareholders are reminded that the Annual General and Special Meeting of Shareholders (the "Meeting") will be held virtually on November 13, 2026. S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom